Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2003

View Archived Issues

Argenta identifies candidate series in Pharmagene IBS collaboration

Glucocorticoid receptor antagonists as a potential alternative therapy for depression

NIAID grant supports development of RNAi approach for hepatitis B treatment

Large Scale Biology awarded HIV vaccine research grant

Positive phase IIIb results for MT-100

Potential use of MCH1 receptor antagonists in anxiety and depression

New data on ST-1535, a novel selective adenosine A2A receptor antagonist

Nemifitide well tolerated in patients with major depression

No discontinuation symptoms following treatment with agomelatine for major depression

Evidence of clinical benefits for COX-2 inhibitors in schizophrenia

Divalproex more effective than gabapentin against aggressive behavior

Reduced risk of relapse with duloxetine in major depression

Ariad scientists design new rapamycin-based immunosuppressants

Yamanouchi claims new BK(Ca) channel openers for use in urinary incontinence

Novel gamma-secretase inhibitors prepared and tested by Schering and Pharmacopeia scientists

Patient dosing begins in phase III satraplatin trial for prostate cancer

Galileo patent covers novel agents for oxidative stress-related disorders

DNA-binding free radical scavengers with potential as chemoprotective agents

Dual Tie-2/VEGFR2 inhibitors claimed by GSK researchers

Aventis enters SARS vaccine development agreement with NIAID

Orphan drug status granted for Voraxaze

FDA requests additional data on lumiracoxib

New phase III trial evaluates Humira for Crohn's disease

Approvable letter issued for Lexapro in GAD

Genentech completes Avastin BLA filing

ZymoGenetics and Serono initiate phase I trial with TACI-Ig

Telomerase-targeting vaccines in development at GemVax

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...